Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Comparing the lasting effects: post COVID vs. non-COVID acute respiratory infections

Symptom profiles between individuals with prior COVID-19 and those with other acute respiratory infections (ARIs).

10 Oct 2023

COVID-19 heightens risk of autoimmune disorders

SARS-CoV-2 infection may elevate risk for certain autoimmune disorders, suggests study. Regular post-COVID monitoring needed to detect and manage potential autoimmune consequences.

9 Oct 2023

Breast milk microbiome changes after COVID-19 vaccination, linked to enhanced infant protection

Study explored the association between BNT162b2 vaccine-induced antibodies and the breast milk microbiome in 49 breastfeeding mothers, revealing that post-vaccination alterations in the microbiome were linked to humoral protection against SARS-CoV-2.

9 Oct 2023

Drug Discovery 2023: A Conversation with Professor Janet Hemingway

We spoke to Professor Janet Hemingway, founding Director of iiCON and Professor of Tropical Medicine at Liverpool School of Tropical Medicine.

From ELRIG (UK) Ltd. 9 Oct 2023

Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

From Sino Biological Inc. 9 Oct 2023

Next-gen intranasal vaccine takes on measles, mumps, and multiple COVID-19 variants in one shot

Researchers developed an intranasal trivalent measles-mumps-SARS-CoV-2 vaccine that provides robust protection against multiple coronavirus variants. Leveraging the established measles-mumps-rubella platform, this vaccine demonstrates broad and adaptable immune responses, especially against Delta and Omicron variants.

8 Oct 2023

Antigenic cartography decodes the mysteries of SARS-CoV-2 variants and vaccines

Using antigenic cartography, researchers analyzed cross-reactivity patterns of SARS-CoV-2 variants and the effect of spike-protein changes on post-infection and vaccination immune responses. The study illuminated unique neutralization profiles and underscored the evolving defense mechanisms with repeated immunizations.

8 Oct 2023

Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.

8 Oct 2023

New method for ultrafast and ultrasensitive quantitative measurement of biological nanoparticles

Can particles as minuscule as viruses be detected accurately within a mere 5 minutes? Osaka Metropolitan University scientists say yes, with their innovative method for ultrafast and ultrasensitive quantitative measurement of biological nanoparticles, opening doors for early diagnosis of a broad range of diseases.

6 Oct 2023

Breakthrough antibody therapy targets Alzheimer's risk gene, offers hope for effective treatment

Researchers introduced and characterized a novel platform based on monoclonal antibodies (mAbs).

6 Oct 2023

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies.

From Bio-Rad Laboratories 6 Oct 2023

Why are most Americans skipping the COVID-19 booster?

A study in the journal Vaccine reveals that misinformation and concerns about side effects are leading reasons why over 80% of eligible Americans have skipped the SARS-CoV-2 vaccine booster. The research underscores the need for more public education about the vaccine's benefits in combating severe COVID-19 infections.

5 Oct 2023

New antibody shows promise in reducing tau proteins associated with Alzheimer's disease

A team led by researchers from Mass General Brigham reports promising results for a monoclonal antibody that takes aim at a new target for Alzheimer's disease.

5 Oct 2023

Organoid medicine reveals promising covid-19 treatment target

When the new SARS-CoV-2 virus began killing thousands of people every week, physicians and scientists around the globe raced to learn why the new pathogen was so deadly.

5 Oct 2023

Study highlights the patient heterogeneity in atopic dermatitis and demonstrates the promises of personalized treatment

Researchers investigated endotype-phenotype associations in atopic dermatitis (AD) beyond its general clinical severity.

4 Oct 2023

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.

From Fluidic Sciences and Sphere Bio 4 Oct 2023

Universal screening: A game-changer in early detection and management of type 1 diabetes

Dr. Emily K. Sims discusses the crucial role of universal type 1 diabetes (T1D) screening in early detection, especially in individuals without a family history, at the EASD Annual Meeting. This proactive approach, aligned with disease-modifying therapies, aims to prevent severe diabetic ketoacidosis episodes, marking a stride towards better management of T1D.

3 Oct 2023

Could infants' robust immune responses reshape future vaccination strategies?

Utilizing next-gen sequencing techniques, researchers analyzed infants' immune responses to infections, uncovering a predominant innate immune activation unlike adults and older children. This insight could steer child vaccination research and pediatric infection management strategies, potentially revolutionizing infant healthcare.

3 Oct 2023

Novel vaccine lowers LDL cholesterol independent of statins

The effectiveness of virus-like particle (VLP)-based vaccines targeting epitopes in the low-density lipoprotein (LDL) receptor.

2 Oct 2023

New study reveals BA.2.86 subvariant's surprising dance with antibodies

Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant's sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.

2 Oct 2023

Antibody News and Research

Further Reading

Comparing the lasting effects: post COVID vs. non-COVID acute respiratory infections

COVID-19 heightens risk of autoimmune disorders

Breast milk microbiome changes after COVID-19 vaccination, linked to enhanced infant protection

Drug Discovery 2023: A Conversation with Professor Janet Hemingway

Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing

Next-gen intranasal vaccine takes on measles, mumps, and multiple COVID-19 variants in one shot

Antigenic cartography decodes the mysteries of SARS-CoV-2 variants and vaccines

Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

New method for ultrafast and ultrasensitive quantitative measurement of biological nanoparticles

Breakthrough antibody therapy targets Alzheimer's risk gene, offers hope for effective treatment

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Why are most Americans skipping the COVID-19 booster?

New antibody shows promise in reducing tau proteins associated with Alzheimer's disease

Organoid medicine reveals promising covid-19 treatment target

Study highlights the patient heterogeneity in atopic dermatitis and demonstrates the promises of personalized treatment

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Universal screening: A game-changer in early detection and management of type 1 diabetes

Could infants' robust immune responses reshape future vaccination strategies?

Novel vaccine lowers LDL cholesterol independent of statins

New study reveals BA.2.86 subvariant's surprising dance with antibodies

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery